Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 6/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249558 | 0.86 | MDM2 (0.36) | MDM2PDK2TP53LMNACYP1A2 | |
| SCHEMBL13185437 | 0.83 | MDM2 (0.34) | MDM2PDK2TP53LMNACYP1A2 | |
| SCHEMBL31003495 | 0.81 | PDK2 (0.46) | MDM2PDK2 | |
| SCHEMBL538738 | 0.79 | PDK2 (0.61) | PDK2 | |
| SCHEMBL12673876 | 0.76 | MEN1 (0.40) | PDK2TP53DRD3OPRM1OPRD1 | |
| SCHEMBL9814079 | 0.73 | AOC3 (0.49) | DRD3 | |
| SCHEMBL7319903 | 0.73 | PDK2 (0.47) | MDM2PDK2SIGMAR1OPRM1CYP1A2 | |
| SCHEMBL13165953 | 0.73 | PDK2 (0.51) | MDM2PDK2SIGMAR1LMNAOPRM1 | |
| SCHEMBL538807 | 0.72 | PDK2 (0.56) | PDK2 | |
| SCHEMBL23588163 | 0.72 | AOC3 (0.50) | DRD3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415744-A1 | FLUORENE COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100240867-A1 | FLUORENE COMPOUND | AJINOMOTO CO. INC. (JP) | 2010-09-23 | — | — | US | disclosed |
| WO-2010104169-A1 | FLUORENE COMPOUND | 味の素株式会社 (JP) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240867-A1 | FLUORENE COMPOUND | NPPA, FURIN, SFPQ | MDM2 150/4885PDK2 3174/4885TP53 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.